11 patents currently held

60 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

2 more records may belong here and await a decision; they are not counted.

The next term ends in May 2034. from the record

Of the 60 now held by other companies, 17 were conveyed to Nimbus Lakshmi Inc. in the filing they arrived in, and 43 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

May 2034

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

202620272028202920302031203220332034 2035 2036 203720382039204020412042204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Rational Drug Design with Computational Free Energy Difference Calculation Using a Modified Bond Stretch Potential US 11,562,808

Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2035.

Ends Mar 2035 · High confidence Also notable

Accounting for Induced Fit Effects US 11,651,840

The newest of the three, granted 2023. It anchors the portfolio to 2039, later than anything else here.

Ends Nov 2039 · High confidence Also notable

Physics-Based Computational Methods for Predicting Compound Solubility US 10,216,911

Granted 2019 and renewed at 2 of 3 maintenance windows. Protection runs to 2037.

Ends May 2037 · High confidence

Formerly held, still cited

Notable

Acc Inhibitors and Uses Thereof US 8,969,557

The most cited patent in this portfolio, cited by 86 later US patents, top 5% of utility patents granted in 2015 in our data. Protection runs to 2032.

conveyed to Nimbus Discovery Inc. - now held by Gilead Apollo, LLC

Ends Nov 2032 · High confidence

Also notable

TYK2 Inhibitors and Uses Thereof US 11,046,698

Cited by 15 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.

conveyed to Nimbus Discovery Inc. - now held by Nimbus Lakshmi, Inc.

Ends Jul 2038 · High confidence

Also notable

SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-Dihydro-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS US 11,034,694

Cited by 20 later US patents, top 10% of utility patents granted in 2021 in our data. Protection runs to 2040.

conveyed to Nimbus Discovery Inc. - now held by Nimbus Saturn, Inc.

Ends Sep 2040 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Jan 25, 2027
The maintenance fee for Methods for Predicting an Active Set of Compounds Having Alternative Cores, and Drug Discovery Methods Involving the Same (US 11,710,543) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

3 of the patents on this record were granted since Aug 16, 2026

What they patent

The 5 largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Physics-Based Computational Methods for Predicting Compound Solubility	2 in force	to May 2037
Rational Drug Design with Computational Free Energy Difference Calculation Using a Modified Bond Stretch Potential	2 in force	to Mar 2035
Tricyclic Compounds Useful in the Treatment of Cancer, Autoimmune and Inflammatory Disorders	1 in force	to May 2043
Heterocyclic Pericondensed CDC7 Kinase Inhibitors for the Treatment of Cancer	1 in force	to Apr 2043
Cyclic Compounds and Methods of Using Same	1 in force	to Mar 2043

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 9,858,395	Binding Affinity Scoring With Penalty For Breaking Conjugation Between Aromatic Ligand Groups In force Term ends May 19, 2034 · High confidence	In force	Term ends May 19, 2034	High confidence
US 12,417,821	Methods and Systems For Calculating Free Energy Differences Using A Modified Bond Stretch Potential In force Term ends Jun 8, 2034 · High confidence	In force	Term ends Jun 8, 2034	High confidence
US 11,562,808	Rational Drug Design with Computational Free Energy Difference Calculation Using a Modified Bond Stretch Potential In force Term ends Mar 18, 2035 · High confidence	In force	Term ends Mar 18, 2035	High confidence
US 10,783,985	Physics-Based Computational Methods for Predicting Compound Solubility In force Term ends Apr 29, 2036 · High confidence	In force	Term ends Apr 29, 2036	High confidence
US 10,216,911	Physics-Based Computational Methods for Predicting Compound Solubility In force Term ends May 14, 2037 · High confidence	In force	Term ends May 14, 2037	High confidence
US 11,710,543	Methods for Predicting an Active Set of Compounds Having Alternative Cores, and Drug Discovery Methods Involving the Same In force Term ends Jul 18, 2039 · High confidence	In force	Term ends Jul 18, 2039	High confidence
US 11,651,840	Accounting for Induced Fit Effects In force Term ends Nov 2, 2039 · High confidence	In force	Term ends Nov 2, 2039	High confidence
US 12,715,876	Cyclic Compounds and Methods of Using Same In force Term ends Mar 4, 2043 · High confidence	In force	Term ends Mar 4, 2043	High confidence
US 12,686,688	Heterocyclic Pericondensed CDC7 Kinase Inhibitors for the Treatment of Cancer In force Term ends Apr 2, 2043 · High confidence	In force	Term ends Apr 2, 2043	High confidence
US 12,667,572	Tricyclic Compounds Useful in the Treatment of Cancer, Autoimmune and Inflammatory Disorders In force Term ends May 30, 2043 · High confidence	In force	Term ends May 30, 2043	High confidence

10 of 11 patents shown.

Pro members see all 11.

Pro members: see all 11 patents

Also on record, not counted in the 11: 60 patents in force now held by others · 1 patent ended · 20 applications pending · 26 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Schrödinger, Inc.